Zacks Research Comments on Prothena FY2027 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Zacks Research issued their FY2027 EPS estimates for shares of Prothena in a report released on Wednesday, March 12th. Zacks Research analyst E. Bagri expects that the biotechnology company will post earnings of ($3.04) per share for the year. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million.

A number of other analysts also recently commented on the stock. StockNews.com upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of Prothena in a research report on Friday, February 21st. Oppenheimer boosted their target price on shares of Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. Finally, Bank of America decreased their price objective on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Prothena Trading Down 2.3 %

PRTA stock opened at $13.74 on Friday. The firm’s 50-day moving average is $14.40 and its two-hundred day moving average is $16.23. Prothena has a 52 week low of $11.70 and a 52 week high of $26.75. The company has a market capitalization of $739.58 million, a price-to-earnings ratio of -5.97 and a beta of -0.02.

Hedge Funds Weigh In On Prothena

A number of hedge funds have recently made changes to their positions in the business. Virtus ETF Advisers LLC grew its holdings in Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 833 shares during the last quarter. Headlands Technologies LLC grew its holdings in Prothena by 196.5% during the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 4,858 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in Prothena during the 4th quarter worth about $145,000. Purkiss Capital Advisors LLC bought a new stake in Prothena during the 4th quarter worth about $149,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Prothena by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,065 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.